Effects of pentoxifylline on the hepatic content of TGF-β1 and collagen in Schistosomiasis japonica mice with liver fibrosis

World Journal of Gastroenterology

Volumn 9, Issue 1, 2003, Pages 152-154

  Xiong, Li Juan ^a   Zhu, Jian Fang ^a   Luo, Duan De ^a   Zen, Lin Lan ^a   Cai, Shu Qing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 3; PENTOXIFYLLINE; PRAZIQUANTEL; SHUANLIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER EXAMINATION; LIVER FIBROSIS; LIVER LEVEL; LOW DRUG DOSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS; STATISTICAL SIGNIFICANCE;

EID: 12244287672     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i1.152     Document Type: Article

References (37)

1. Qing JP, Jiang MD. Phenotype and regulation of hepatic stellate cell and liver fibrosis. Shijie Huaren Xiaohua Zazhi 2001; 9: 801-804
2. Dai WJ, Jiang HC. Advances in gene therapy of liver cirrhosis: A review. World J Gastroenterol 2001; 7: 1-8
3. Wang GQ, Lu HQ, Wang H, Kong XT, Zhong RQ, Huang C, Gao F. Effects of Decorin on collagen of hepatic stellate cells. Xin Xiaohuabingxue Zazhi 2001; 9: 1395-1398
4. Wang JY, Guo JS, Yang CQ. Expression of exogenous rat collagenase in vitro and in a rat model of liver fibrosis. World J Gastroenterol 2002; 8: 901-907
5. Zhang YT, Chang XM, Li X, Li HL. Effects of spironolactone on expression of type I/III collagen proteins in rat hepatic fibrosis. Xin Xiaohuabingxue Zazhi 2001; 9: 1120-1124
6. Jiang SL, Yao XX, Sun YF. Therapy of liver fibrosis. Shijie Huaren Xiaohua Zazhi 2000; 8: 684-686
7. Okazaki I, Watanabe T, Hozawa S, Niioka M, Arai M, Maruyama K. Reversibility of hepatic fibrosis: From the first report of collagenase in the liver to the possibility of gene therapy for recovery. Keio J Med 2001; 50: 58-65
8. Reis LF, Ventura TG, Souza SO, Arana-Pino A, Pelajo-Machado M, Pereira MJ, Lenzi HL, Conceicao MJ, Takiya CM. Quantitative and qualitative interferences of pentoxifillyne on hepatic Schistosoma mansoni granulomas: Effects on extracellular matrix and eosinophil population. Mem Inst Oswaldo Cruz 2001; 96: 107-112
9. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002; 50: 241-247
10. Jiang HQ, Zhang XL. Mechanism of liver fibrosis. Shijie Huaren Xiaohua Zazhi 2000; 8: 687-689
11. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW. Prediction of progressive liver fibrosis in hepatic C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001; 8: 430-437
12. Chen WX, Li YM, Yu CH, Cai WM, Zheng M, Chen F. Quantitative analysis of transforming growth factor beta1 mRNA in patients with alcoholic liver disease. World J Gastroenterol 2002; 8:379-381
13. Kmiec Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001; 161: 1-151
14. Du WD, Zhang YE, Zhai WR, Zhou XM. Dynamic changes of type I,III and IV collagen synthesis and distribution of collagen-producing cells in carbon tetrachloride-induced rat liver fibrosis. World J Gastroenterol 1999; 5: 397-403
15. Bissell DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001; 33: 179-190
16. Schuppan D, Koda M, Bauer M, Hahn EG. Fibrosis of liver, pancreas and intestine: Common mechanisms and clear targets? Acta Gastroenterol Belg 2000; 63: 366-370
17. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997; 29: 181-196
18. Preaux AM, Mallat A, Rosenbaum J, Zafrani ES, Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997; 26: 315-322
19. Desmouliere A, Xu G, Costa AM, Yousef LM, Gabbiani G, Tuchweber B. Effects of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999; 30: 621-631
20. Moser M, Zhang M, Gong Y, Johnson J, Kneteman N, Minuk GY. Effects of preoperative interventions on outcome following liver resection in a rat model of cirrhosis. J Hepatol 2000; 32: 287-292
21. Wu J, Zern MA. Hepatic stellate cells: A target for the treatment of liver fibrosis. J Gastroenterol 2000; 35: 665-672
22. Reeves HL, Friedman SL. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 2002; 7: D808-826
23. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res 1999; 23: 911-916
24. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451
25. Beljaars L, Meijer DK, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002; 7: e214-222
26. Wu J, Zern MA. Hepatic stellate cells: A target for the treatment of liver fibrosis. J Gastroenterol 2000; 35: 665-672
27. Liu T, Hu JH, Cai Q, Ji YP. The signal transducting molecular in HSC. Shijie Huaren Xiaohua Zazhi 2001; 9: 805-807
28. Huang GC, Zhang JS. Activated in vivo signal transduction of HSC. Xin Xiaohuabingxue Zazhi 2001; 9: 1056-1060
29. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, Ten Dijke P, Gressner AM. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett 2001; 502: 1-3
30. Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrubias-Pinedo A, Rojkind M. Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 1999; 29: 960-970
31. Yata Y, Gotwals P, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: Implications for antifibrotic therapy. Hepatology 2002; 35: 1022-1030
32. Tahashi Y, Matsuzaki K, Date M, Yoshida K, Furukawa F, Sugano Y, Matsushita M, Himeno Y, Inagaki Y, Inoue K. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49-61
33. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, Suzuki Y, Kojima S. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120: 1784-1800
34. Breitkopf K, Lahme B, Tag CG, Gressner AM. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001; 33: 387-396
35. Suzuki C, Kayano K, Uchida K, Sakaida I, Okita K. Characteristics of the cell proliferation profile of activated rat hepatic stellate cells in vitro in contrast to their fibrogenesis activity. J Gastroenterol 2001; 36: 322-329
36. Liu F, Liu JX. The role of transforming growth factor beta1 in liver fibrosis. Shijie Huaren Xiaohua Zazhi 2000; 8: 86-88
37. Preaux AM, Mallat A, Nhieu JT, D'Ortho MP, Hembry RM, Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999; 30: 944-950